Wave Life Sciences Ltd. has reported that GSK plc has selected its first two programs to advance to development candidates following achievement of target validation as part of the companies’ ongoing collaboration.
Curevac NV and The University of Texas MD Anderson Cancer Center have entered into a co-development and licensing agreement to develop novel mRNA-based cancer vaccines.
Mina Therapeutics Ltd. has announced a research collaboration and licensing agreement option with Nippon Shinyaku Co. Ltd. for the discovery and potential development and commercialization of small activating RNA (RNAa) therapeutic candidates targeting rare neurodegenerative diseases for which there are currently no treatment options.